Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Trial Profile

NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms QUILT-3.052
  • Sponsors ImmunityBio
  • Most Recent Events

    • 23 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 26 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
    • 02 Jun 2017 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top